Literature DB >> 10405433

Diagnostic value of anti-hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation.

C Casino1, D Lilli, D Rivanera, A Comanducci, M Rossi, G Casciaro, I Pecorella, D Alfani, C Mancini.   

Abstract

The significance of anti-hepatitis C virus (HCV) core immunoglobulin M (IgM) and its relationship with genotypes, alanine aminotransferase abnormality, and histological data were studied for 18 patients who had undergone orthotopic liver transplantation due to HCV-related end-stage disease. During follow-up, IgM response seemed to be associated with the recurrence of HCV infection but did not correlate with abnormal alanine aminotransferase levels and histological data. In addition, the results of this study indicated that the detection of HCV RNA is critical for diagnosis of reinfection in liver transplantation.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10405433      PMCID： PMC85330     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  23 in total

1.  Significance of IgM anti-HCV core level in chronic hepatitis C.

Authors:  G V Papatheodoridis; J K Delladetsima; A Katsoulidou; V Sypsa; M Albrecht; G Michel; A Hatzakis; N C Tassopoulos
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

2.  Hepatitis C virus recurrence after liver transplantation: relationship to anti-HCV core IgM, genotype, and level of viremia.

Authors:  J Crespo; B Carte; J L Lozano; F Casafont; M Rivero; F de la Cruz; F Pons-Romero
Journal:  Am J Gastroenterol       Date:  1997-09       Impact factor: 10.864

3.  Hepatitis C viral RNA in serum of patients with chronic non-A, non-B hepatitis: detection by the polymerase chain reaction using multiple primer sets.

Authors:  K Cristiano; A M Di Bisceglie; J H Hoofnagle; S M Feinstone
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

4.  Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.

Authors:  J M Pawlotsky; M Pellerin; M Bouvier; F Roudot-Thoraval; G Germanidis; A Bastie; F Darthuy; J Rémiré; C J Soussy; D Dhumeaux
Journal:  J Med Virol       Date:  1998-04       Impact factor: 2.327

5.  Immunoglobulin M anti-hepatitis C virus core antibodies correlate with hepatitis C recurrence in liver graft recipients.

Authors:  F Negro; E Giostra; L Rubbia-Brandt; G Mentha; H Troonen; M Albrecht; G Michel; L Perrin; P Morel; A Hadengue
Journal:  Transplant Proc       Date:  1996-10       Impact factor: 1.066

6.  Hepatitis C virus-specific B cell activation: IgG and IgM detection in acute and chronic hepatitis C.

Authors:  I Quinti; N F Hassan; D El Salman; H Shalaby; D El Zimatty; M K Monier; R R Arthur
Journal:  J Hepatol       Date:  1995-12       Impact factor: 25.083

7.  The significance of immunoglobulin M antibody response to hepatitis C virus core protein in patients with chronic hepatitis C.

Authors:  N Yuki; N Hayashi; K Ohkawa; H Hagiwara; M Oshita; K Katayama; Y Sasaki; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1995-08       Impact factor: 17.425

8.  Quantitative assessment of hepatitis C virus RNA and IgM antibodies to hepatitis C core in chronic hepatitis C.

Authors:  A L Martinelli; D Brown; H B Braun; G Michel; G M Dusheiko
Journal:  J Hepatol       Date:  1996-01       Impact factor: 25.083

9.  IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation.

Authors:  F Negro; E Giostra; L Rubbia-Brandt; G Mentha; G Colucci; P Morel; R Quadri; L Perrin; A Hadengue
Journal:  J Med Virol       Date:  1998-11       Impact factor: 2.327

10.  Long-term outcome of hepatitis C infection after liver transplantation.

Authors:  E J Gane; B C Portmann; N V Naoumov; H M Smith; J A Underhill; P T Donaldson; G Maertens; R Williams
Journal:  N Engl J Med       Date:  1996-03-28       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.